



**LUNG CANCER RESEARCH
(CHARITY COMMISSION NO. 1101823)**

ACCOUNTS

31 DECEMBER 2024

**LUNG CANCER RESEARCH
(CHARITY COMMISSION NO. 1101823)**

ACCOUNTS FOR THE YEAR ENDED 31 DECEMBER 2024

CONTENTS	PAGE
Trustees' Report	1 - 5
Accountants' Report	6
Independent Examiners Report	7
Balance Sheet	8
Statement of Financial Activities	9
Notes to the Accounts	10

TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

Registered Charity Number	1101823
Principal Address	c/o Kreston Reeves LLP, 168 Shoreditch High Street, 2nd Floor, London, E1 6RA
Governing Document	Settlement Deed dated 20th January 2004
How Constituted	As a trust
Objects of the Charity	<p>The assets are held on trust to fund clinical laboratory and epidemiological research into the causes, prevention and treatment of Lung Cancer.</p> <p>In setting our objectives and planning our activities the Trustees have given careful consideration to the Charity Commission's general guidance on public benefit.</p>
Accountants	Kreston Reeves LLP 2nd Floor, 168 Shoreditch High Street London E1 6RA
Bankers	HSBC Bank Plc 12 Hampstead High Street Hampstead London NW3 1PY
Trustees	Robin Ellison (retired 17th February 2025) Alastair Meeks Michael Seckl Nicci Wyborn
Trustee Selection	Appointment by existing trustees

MISSION STATEMENT

Introduction

Lung Cancer Research was established as a registered charity in 2004 to support the research in the field of lung cancer.

Lung cancer is poorly supported by the mainstream cancer charities, partly because it is seen as a self-inflicted disease in many cases.

There are four trustees of the charity:

Robin Ellison (retired 17th February 2025)
Mr Alastair Meeks
Professor Michael Seckl
Ms Nicci Wyborn

Professor Ellison and Alastair Meeks are experienced trust lawyers. Professor Seckl is a world-leading researcher in the field of lung cancer. Ms Wyborn is a lung cancer survivor.

TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

Alastair Meeks

Alastair Meeks is a retired solicitor. Until May 2020 he was a partner in Pinsent Masons and practised pensions law.

He was chair of the Association of Pension Lawyers from 2007 to 2009 and is a Fellow of the Pensions Management Institute.

He acted in relation to many landmark pension cases, including the ITN case and BESTrustees v Stuart, both of which explored the interaction between explanatory literature and trust documentation. He acted for the trustees of Anglo United Pension Scheme and the Dexion Scheme, and in the process helped prompt the establishment of the DWP's Financial Assistance Scheme.

He is the author of Tolley's Pensions Cases, the definitive work on the subject and currently edits the pensions cases section of Tolley's Pensions Law.

He is now taking up a role as a professional trustee with Zedra as from October 2023.

Professor Seckl

Michael Seckl, MD, PhD, FMedSci trained medicine and science at University College London (United Kingdom) obtaining a BSc in immunology in 1983 and his MBBS in 1986. He did his general professional and specialist medical oncology training on the London circuit, and became a fellow of the Royal College of Physicians. He obtained his PhD in biochemistry in 1995 from the London Research Institute (now known as the CRICK)/University College London and was that year appointed as a senior lecturer/honorary consultant in medical oncology at Charing Cross Hospital in London, now part of Imperial College London.

He then established his own research groups working on cell signalling in lung cancer and trophoblastic cancers supported by grants from Cancer Research UK, the Medical Research Council, Wellcome Trust, Wellbeing, industry, and others. He was promoted to reader in 2002 and professor of molecular oncology in 2004, when he also took on the directorship of the Charing Cross Gestational Trophoblastic Disease Centre and the supraregional Tumour Marker Assay Service.

Professor Seckl also leads the Imperial College Experimental Cancer Medicine Centre, the Imperial Cancer Trials unit, runs the London Lung Cancer Alliance and has run multiple Phase I-III trials. He is on the editorial board of several journals and chairs/sits on several grants committees. He is the immediate past-president of the Royal Society of Medicine Oncology section and European Organisation for the Treatment of Trophoblastic Disease. He was also past president and is the current treasurer of the International Society for the Study of Trophoblastic Disease and holds an honorary professorship with the Peking Union Medical College in China.

He also established and now co-leads the gynaecological cancer domain within the European Rare Adult Cancer Network (EURACAN). Educationally, he was director of postgraduate studies for the Department of Surgery and Cancer with overall responsibility for 200 MSc/MRes and 400 PhD students between 2012-2022.

Within his own research group, he and his team have received numerous national and international awards and in the past 5 years have raised over £18M of grant income. He has published over 280 peer reviewed manuscripts many appearing in leading scientific and medical journals such as Lancet, Lancet Oncology, New England J of Medicine, Nature communications, Science Translational Medicine and J Clinical Oncology. In recognition for his contributions to medical science and his international leadership he was made a Fellow of the Academy of Medical Sciences in 2017. He remains committed to teaching, research, and his patients.

TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

Nicci Wyborn

Nicci is a Senior Pensions Consultant in the Pinsent Masons Pensions Solutions business at Pinsent Masons. In her current role she specialises in risk, governance and project management services for clients with both defined benefit (DB) and defined contribution (DC) pension schemes, working closely with trustee boards, Pensions Managers and HR Directors. Clients include a £5.5 billion pension scheme (DB/DC), a £1 billion pension scheme (DB/with AVCs), a £700 million pension scheme (open DB) and £300 million pension scheme (DB/DC). Nicci had been at Pinsent Masons for nearly 23 years starting her career as a PA in the pensions group, before moving to Pinsent Masons Pensions Solutions in 2017. Nicci had lung surgery in 2018 for a carcinoid lung tumour so the work funded by the charity is extremely important to her.

I declare that in my capacity of charity trustee, that:

- the Trustees have approved the report above; and
- have authorised me to sign it on their behalf.



Alastair Meeks
Trustee

ACCOUNTANTS' REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

In accordance with the engagement letter of 3 September 2013 we have prepared the accounts, set out on pages 8 to 10, from the accounting records of the Trustees and information and explanations given to us.

These accounts have been compiled in accordance with the accounting policies set out in Note 1 to these accounts. These accounts are not intended to comply fully with the provisions of 'UK Generally Accepted Accounting Principles'.

This report is made to the Trustees of Lung Cancer Research Trust, in accordance with the terms of our engagement. Our work has been undertaken so that we might prepare the accounts, report that we have done so and state those matters which we feel should be drawn to the Trustees' attention and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone, other than the Trustees, for our work or for this report.

We have carried out this engagement in accordance with technical guidelines issued by the Institute of Chartered Accountants in England & Wales and by the Society of Trust and Estate Practitioners. We have compiled this report with ethical guidance laid down by those bodies.

We have not been instructed to carry out an audit of these accounts. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations given to us and we do not, therefore, express any opinion on these accounts.

Kreston Reeves LLP

Kreston Reeves LLP
Chartered Accountants
2nd Floor
168 Shoreditch High Street
London
E1 6RA

ACCOUNTS APPROVAL CERTIFICATE

We approve these accounts and confirm that we have made available all relevant records and information for their preparation.

Robin Ellison

Alastair Meeks

[Signature]
DUTY AUTHORISED BY ALL TRUSTEES

Michael Seckl

Nicci Wyborn

INDEPENDENT EXAMINER'S REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

I report on the accounts for the year ended 31st December 2024 which are set out on pages 8 to 10.

Respective Responsibilities of Trustees and Examiner

The charity's trustees are responsible for the preparation of the accounts. The charity's trustees consider that an audit is not required for this year under section 144 of the Charities Act 2011 ("the Charities Act") and that an independent examination is needed.

It is my responsibility to:

- examine the accounts under section 145 of the Charities Act,
- to follow the procedures laid down in the general Directions given by the Charity Commission (under section 145(5)(b) of the Charities Act, and
- to state whether particular matters have come to my attention.

Basis of Examiner's Report

My examination was carried out in accordance with general Directions given by the Charity Commission. An examination includes a review of the accounting records kept by the charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts, and seeking explanations from the trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit, and consequently no opinion is given as to whether the accounts present a 'true and fair' view and the report is limited to those matters set out in the statement below.

Independent Examiner's Report

In connection with my examination, no matter has come to my attention:-

- 1 Which gives me reasonable cause to believe that in any material respect the requirements
 - to keep accounting records in accordance with Section 130 of the Charities Act; and
 - to prepare accounts which accord with the accounting records and to comply with the accounting requirements of the Charities Acthave not been met; or
- 2 to which, in my opinion, attention should be drawn in order to enable a proper understanding of the accounts to be reached.



Jerry Canny FCCA, CPA
Canny & Associates
Chartered Certified Accountants
60 Cannon Street
London
EC4N 6NP

26.01.2026

Date

LUNG CANCER RESEARCH
(CHARITY COMMISSION NO. 1101823)

BALANCE SHEET AS AT 31 DECEMBER 2024

		UNRESTRICTED FUNDS	UNRESTRICTED FUNDS
		31 December 2024	31 December 2023
	Note	£	£
Current assets			
HSBC Bank Plc		340,966	370,100
Total cash funds		<u>340,966</u>	<u>370,100</u>
Creditors within one year			
Accountancy charges		4,200	4,080
Independent Examination charges		900	-
		<u>5,100</u>	<u>4,080</u>
Net assets		<u>335,866</u>	<u>366,020</u>
Funds of the Charity			
Cash funds brought forward, 31 December 2023		366,020	471,656
Net receipts/(payments) during the year		(30,154)	(105,636)
Total funds		<u>335,866</u>	<u>366,020</u>

Signed by the Trustees on..... 31 October 2025

Robin Ellison

Alastair Meeks *Only Authorised By All Trustees*

Michael Seckl

Nicci Wyborn

STATEMENT OF FINANCIAL ACTIVITIES (SOFA) FOR THE YEAR ENDED 31 DECEMBER 2024

		UNRESTRICTED FUNDS	UNRESTRICTED FUNDS
		31 December 2024	31 December 2023
	Note	£	£
Incoming resources			
Donations received	3	67,744	9,071
Total incoming resources		<u>67,744</u>	<u>9,071</u>
Resources expended			
Accountancy charges		2,100	2,100
Independent Examination charges		900	-
Bank charges		116	133
Imperial College for funding for lung cancer research		94,496	111,507
Administration Expenses		286	917
Registration with the Fundraising Regulator		-	50
Total resources expended		<u>97,898</u>	<u>114,707</u>
Net movement in funds		(30,154)	(105,636)
Total funds brought forward, 31 December 2023		366,020	471,656
Total funds as at 31 December 2024		<u>335,866</u>	<u>366,020</u>

NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31 DECEMBER 2024

1 Accounting policies

- 1.1 Provision is included for all known current liabilities. Contingent and future liabilities are not included, except where mentioned below by narrative note.
- 1.2 Assets are shown at their value at the balance sheet date.

2 Income Tax (IT), Capital Gains Tax (CGT) and Inheritance Tax (IHT)

- 2.1 The trust, as a charity, is exempt from IT and CGT on its investment income and capital gains. None of the restrictions on this relief, imposed by tax legislation, apply for this year.
- 2.2 The trust is also exempt from IHT while its funds continue to be held or applied for charitable purposes.

3 Donations

The Trustees received the following donations during this year:-

	2024	2023
	£	£
Multiple payments		
Charities Trust	745	603
Charitable Giving	80	120
Charities Aid Foundation	275	110
Paypal Giving Fund	-	4,216
Just Giving	24,592	4,022
Memory Giving	221	-
Other	3,991	-
Single payments		
Donatis	303	-
Legacies from estates		
Christine Bellamy	37,537	-
	<u>67,744</u>	<u>9,071</u>